NATCO Launches TAFNAT for Hepatitis B Treatment | CORPORATE ETHOS

NATCO Launches TAFNAT for Hepatitis B Treatment

By: | December 18, 2017
natco

Dec 18: Drug maker Natco Pharma Ltd on Monday announced that it has launched a generic version of Tenofovir Alafenamide, TAF, 25 mg, a once-daily tablet for the treatment of chronic hepatitis B in adults, under its brand TAFNAT, in India.

According to the company, the drug TAF demonstrates comparable efficacy, with an enhanced renal and bone safety profile as compared to earlier formulation of tenofovir (tenofovir disoproxil fumarate).

TAFNAT is manufactured under license from Medicines Patent Pool (MPP) and Gilead Sciences.

“Natco priced its generic medicine of TAFNAT at an MRP of Rs 1,900 for a monthly pack of 30 tablets for the India market,” the company said.